{"url_path":"/sec/tvrd/8-k/2026-05-08/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1346830/0001104659-26-057524-index.html","accession_number":"0001104659-26-057524","cik":"0001346830","ticker":"TVRD","issuer_name":"Tvardi Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1346830/0001104659-26-057524-index.html","primary_entity_key":"0001346830","primary_entity_name":"Tvardi Therapeutics, Inc."},"word_count":159,"has_tables":true,"body_markdown":"**Item 2.02. Results of Operations and Financial Condition.**\n\n \n\nOn May 8, 2026, Tvardi Therapeutics,\nInc. (the “Company”) issued a press release announcing its financial results and business highlights for the fiscal quarter\nended March 31, 2026. A copy of the Company’s press release dated May 8, 2026 is attached hereto as Exhibit 99.1 and is incorporated\nherein by reference.\n\n \n\nThe information contained\nherein and the accompanying Exhibit 99.1 is being furnished under “Item 2.02 Results of Operations and Financial Condition”\nand shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise\nsubject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed\nincorporated by reference in any filing with the Securities and Exchange Commission made by us, whether made before or after the date\nhereof, regardless of any general incorporation language in such filing."}